Direct Assessment Of Iga And Igg Paraprotein By Hevylite Assay And Correlation To Imwg Response And Progression-Free Survival In Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients In The Prospective Phase Iii Gmmg-Mm5 Trial

Background: Response criteria in myeloma have been developed to predict treatment outcome and to compare results from clinical trials. The current IMWG response criteria (Kumar, Lancet Oncology 2016) are based on paraprotein assessment by immunofixation and electrophoresis of serum and urine. The hevylite (HLC) assay directly quantifies the kappa and lambda fractions of IgG, IgA and IgM as well as the corresponding kappa/lambda ratios. To compare the response assessment by IMWG criteria and by HLC we applied the test to serum samples from the prospective GMMG MM5 trial in newly diagnosed myeloma patients.